AXS-12 reduced the frequency of cataplexy attacks per week compared with placebo (P =.017). Topline results were announced from a phase 3 trial evaluating AXS-12 (reboxetine) in patients with ...

Vaccination of 'mid-adults,' including those at higher risk, results in higher number needed to vaccinate than that seen for younger people ...

There was an increase in quarterly prescription rates from 4.2% in July to September 2021 to 23.5% in July to September 2023. (HealthDay News) — From 2021 to 2023, there was an increase in ...

According to Soleno Therapeutics, the FDA required more time to review responses to recent information requests.

STS101 is an investigational DHE nasal powder product administered through a proprietary nasal delivery device.

According to the Company, detailed results will be presented at a medical meeting in 2025. A phase 3 trial evaluating tiragolumab in combination with Tecentriq ® (atezolizumab) in adults with PD-L1 ...

Seasonal maternal RSV vaccination may be cost-effective, as well as nirsevimab, particularly for those with higher risks ...

(HealthDay News) — Exposure to certain antiseizure medications (ASMs) in utero is associated with an increased likelihood of neurodevelopmental diagnoses, according to a study published online Nov. 15 ...

Participants were randomly assigned to receive subcutaneous sotatercept or placebo every 21 days with background PAH therapy. The primary endpoint was the time to first confirmed morbidity or ...

The researchers used the Baltimore Longitudinal Study of Aging, a prospective cohort study of community-dwelling older adults.

Imkeldi is a liquid formulation of imatinib that utilizes proprietary technology to allow for accurate dosing and an alternative formulation to tablets.

Vutrisiran, a transthyretin-directed small interfering RNA therapeutic, is currently approved under the brand name Amvuttra ® for the treatment of polyneuropathy manifestations of hereditary ...